Evaluating Safety and Effectiveness of PCSK9 Inhibitors with Statins in Adults Aged 18-80 with Large-Artery Atherosclerotic Ischemic Stroke

What this Trial Is About

Researchers are evaluating the effectiveness and safety of early PCSK9 inhibitor therapy in adults aged 18 to 80 who have experienced a large-artery atherosclerotic ischemic stroke. The study compares patients treated with evolocumab plus statin therapy to those receiving statin therapy alone, focusing on neurological improvement, lipid reduction, functional outcomes at 90 days, recurrent cardiovascular events, and safety. Participants will be assigned to one of two groups based on their routine clinical care one group will receive evolocumab injections 140 mg every 2 weeks or 420 mg monthly plus daily statins for 90 days, while the other group will receive only daily statin therapy for the same period. The study is conducted across multiple centers and includes baseline, day 7 or hospital discharge, day 30, and day 90 visits for assessments. During the study, participants will undergo evaluations including neurological scales and lipid measurements at scheduled visits. Researchers will monitor functional outcomes using the modified Rankin Scale at 90 days, track early neurological changes, recurrent events, and mortality. Safety follow-up continues through day 90 even if evolocumab treatment stops. Total participation spans approximately 90 days post-stroke onset.

Efficacy and Safety of PCSK9 Inhibitors in Patients With Large-Artery Atherosclerosis (LAA) Ischemic Stroke